A new optical device using visible light photoplethysmography accurately measured blood glucose in patients with diabetes, achieving a MARD of 8.8% and 100% clinical agreement in the Consensus Error Grid....
A retrospective cohort study presented at the American Diabetes Association found that combining continuous glucose monitoring (CGM) with GLP-1 agonist therapy led to significantly greater reductions in...
A real-world study of a fasting mimicking diet program showed improved glycemic control, medication reduction, and weight loss in people with type 2 diabetes, with high engagement and satisfaction rates....
A post hoc analysis of the SURMOUNT-1 trial reveals that cardiometabolic improvements achieved after 176 weeks of tirzepatide may diminish significantly within 17 weeks of treatment cessation, particularly...
In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing patients with diabetes and the value of utilizing the services of a...
In a recent retrospective cohort study, researchers examined changes in the medication regimens of patients with type 2 diabetes following the initiation of second-line therapy.
Researchers investigated semaglutide’s impact on weight-related muscle loss and its potential impact on spinal surgical outcomes, specifically transforaminal lumbar interbody fusion.
In this COVID-19 roundup, the CDC reports a record low number of COVID-19 hospitalizations, metformin reduces the likelihood of SARS-CoV-2 Viral load and rebound, remdesivir reduces mortality in older...
A team of researchers sought to establish the association between patients with diabetic retinopathy and quality of life, including vision-related quality of life.
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
